摘要
目的探讨定量检测血清肿瘤标志物CA125在肝硬化合并腹水患者中的临床意义,评价CA125作为肝硬化腹水生物学标志物的价值。方法回顾性分析2015年6月至2015年12月于本院住院的461例肝硬化患者的临床数据,根据患者腹水量分为无腹水组(149例)、少量腹水组(152例)和中-大量腹水组(160例)。采用Spearman等级相关分析及受试者工作特征曲线分析CA125在腹水患者中的临床意义。结果血清CA125与肝硬化患者腹水量呈正相关(ρ=0.803,P<0.0001)。CA125对于腹水定性的诊断临界值为34.7 U/ml,AUROC为0.958,敏感度为88.5%,特异度为95.3%,阳性似然比为18.83,阴性似然比为0.12。CA125对于腹水定量的诊断临界值为72.2 U/ml,AUROC为0.801,敏感度为62.5%,特异度为87.5%,阳性似然比为5.00,阴性似然比为0.43。结论血清CA125可作为预测肝硬化并发腹水短期临床转归的生物学标志物。
Objective To investigate the clinical significance of serum CA125 in cirrhotic patients with ascites,and to evaluate the value of CA125 as the biomarker of ascites.Methods Clinical data of 461 cases with liver cirrhosis from June 2015 to December 2015 in our hospital were retrospectively analyzed.All the patients were divided into non ascites group,little ascites group and middle to large ascites group according to the amount of ascites.Spearman＇s rank correlation and receiver operating characteristic（ROC） curve were used to analyze the clinical significance of CA125 in liver cirrhosis patients with ascites.Results Serum CA125 level was positively correlated with the degree of ascites（p = 0.803,P 0.0001）.The cut-off value of CA125 in ascites qualitative analysis was 34.7 U/ml,and the AUROC,sensitivity,specificity,positive likelihood ratio and negative likelihood ratio were 0.958,88.5%,95.3%,18.83 and 0.12,respectively.The cutoff value of CA125 in ascites quantitative analysis was 72.2 U/ml,and the AUROC,sensitivity,specificity,positive likelihood ratio and negative likelihood ratio were 0.801,62.5%,87.5%,5.00,and 0.43,respectively.Conclusion The serum CA125 might be used as a biomarker in prediction of short-term outcome of liver cirrhosis patients with ascites.
出处
《中国肝脏病杂志（电子版）》
CAS
2017年第2期62-66,共5页
Chinese Journal of Liver Diseases：Electronic Version
基金
北京市自然科学基金面上项目(7122177)
国家自然科学基金面上项目(81371799)
中国肝炎防治基金会王宝恩肝纤维化研究基金重点项目(2011xjs0408)
